MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on February 16, 2023, 09:40:21 am

Title: (Lancet editorial) Towards equitable access to treatment for MS
Post by: agate on February 16, 2023, 09:40:21 am

Editorial in the March 2023 issue of The Lancet Neurology, "Towards equitable access to treatment for multiple sclerosis":


https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00041-8/fulltext?dgcid=raven_jbs_etoc_email

Title: MS International Federation application to WHO for inclusion of 3 MS drugs in ESL
Post by: agate on March 26, 2023, 09:16:05 pm

The MS International Federation's application to WHO (the World Health Organization) for inclusion of three MS treatments (Rituxan, glatiramer acetate, and Cladribine) in the Essential Medicines List (EML) can be seen here:




https://bit.ly/3FW7HSO

Title: WHO lists 3 MS drugs as essential
Post by: agate on July 27, 2023, 08:55:53 pm

This amounts to an international acknowledgment that at least 3 MS drugs are important enough to be made available worldwide.

From Reuters (July 26, 2023)--"Obesity drugs don't make WHO's essential list, but Ebola, MS drugs added":


https://tinyurl.com/ymd6etxb